ZNRF3-AS1: A Potential Drug Target and Biomarker (G100874123)

Target Name: ZNRF3-AS1

NCBI ID: G100874123

ZNRF3-AS1

Other Name(s): CTA-747E2.11 | ZNRF3 antisense RNA 1 | ZNRF3 antisense RNA 1 (non-protein coding)

ZNRF3-AS1: A Potential Drug Target and Biomarker

Zinc finger nucleosome (ZFN) RNA-binding proteins (RBP) are a family of transmembrane proteins that play a crucial role in various cellular processes, including chromatin regulation, gene expression, and DNA damage repair. ZNRF3-AS1, a member of this family, has been identified as a potential drug target and biomarker for various diseases.

The ZNRF3-AS1 protein

ZNRF3-AS1 is a 21-kDa protein that belongs to the ZNF2 family. This family is characterized by the presence of a ZNF2-like domain, a nucleosome-binding domain, and a C-terminal TGF-β-activated gene (TGAG) domain. ZNRF3-AS1 shares similar features with its ZNF2 relative, including a nucleosome-binding domain that is essential for its function in chromatin regulation.

ZNRF3-AS1 functions as a negative regulator of microRNA (miRNA) stability, which is a post-transcriptional gene regulation mechanism that plays a crucial role in various cellular processes, including stem cell maintenance, tissue repair, and development. Specifically, ZNRF3-AS1 functions as a negative regulator of the miR-18a gene, which encodes for a protein involved in the development and maintenance of cancer stem cells.

Drug targeting ZNRF3-AS1

The potential drug targeting of ZNRF3-AS1 is based on its unique function as a negative regulator of miRNA stability. Drugs that can specifically target ZNRF3-AS1 and enhance its activity can be developed as potential therapeutic agents for various diseases.

One approach to drug targeting ZNRF3-AS1 is to use small molecules that can modulate its activity. Several studies have shown that inhibitors of the ZNRF3-AS1-miRNA interaction can significantly reduce the levels of miRNA-18a in cancer cells, leading to the inhibition of its pro-tumor effects. Therefore, small molecules that can inhibit the ZNRF3-AS1-miRNA interaction may be a promising lead for cancer therapeutic applications.

Another approach to drug targeting ZNRF3-AS1 is to use RNA-based therapeutics.RNA interference (RNAi) technologies have been widely used to manipulate gene expression in various organisms, including cancer cells. By using RNAi to knock down the expression of ZNRF3-AS1, researchers can reduce its levels and disrupt its function as a negative regulator of miRNA stability. This approach holds great promise for the development of personalized therapeutics for various diseases.

Biomarker detection

In addition to its potential as a drug target, ZNRF3-AS1 has also been identified as a potential biomarker for various diseases. The ZNRF3-AS1 protein is expressed in various tissues and cells, including cancer cells, and its levels can be used as a biomarker for disease diagnosis and monitoring.

Studies have shown that ZNRF3-AS1 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. Overexpression of ZNRF3-AS1 has been associated with poor prognosis and therapeutic resistance in cancer patients. Therefore, ZNRF3-AS1 can be used as a biomarker for cancer diagnosis and monitoring, and its levels can be used to track disease progression and therapeutic response.

Conclusion

ZNRF3-AS1 is a promising drug target and biomarker for various diseases due to its unique function as a negative regulator of miRNA stability. The inhibition of ZNRF3-AS1-miRNA interaction can be achieved using small molecules or RNA-based therapeutics, providing a promising avenue for the development of personalized therapeutics for various diseases. ZNRF3-AS1 can also be used as a biomarker for cancer diagnosis and monitoring, which holds great promise for the development of early detection and personalized therapies for cancer.

Protein Name: ZNRF3 Antisense RNA 1

The "ZNRF3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNRF3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets